Long-Term Cholesterol Management: How Sustained Treatment Works

Long-Term Cholesterol Management: How Sustained Treatment Works

---

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention. These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

---

In Brief

Cholesterol management is not an acute treatment. It is cumulative exposure management — sustained reduction in the atherogenic particle burden that circulates through coronary arteries over decades.

The clinical trial evidence is clear: larger and longer LDL reductions produce larger and longer reductions in cardiovascular events. (1)

What breaks the evidence-to-outcome chain is not biology — it is discontinuation. In routine care, roughly half of patients stop or interrupt statin therapy within the first one to two years. (12) The gap between what treatment can do and what it actually delivers at the population level is driven predominantly by behavioral and systems factors.

This article covers three things: why people stop treatment, why that matters biologically, and — drawing on research into chronic disease self-management — what systems reliably sustain long-term adherence better than motivation alone.

The Biology of Cumulative Exposure

Most patients who stop cholesterol treatment feel no worse for stopping. LDL rises silently. Atherosclerosis progresses silently. No signal tells them that damage is accumulating.

This is the fundamental problem of long-term preventive therapy: the benefit is real and substantial, and entirely invisible.

The clinical relevance of sustained exposure is not intuitive, but it is the single most important concept in long-term cholesterol management. Cardiovascular risk is not determined by a snapshot of today’s LDL. It is determined by how long atherogenic particles have been circulating at elevated concentrations — the cumulative arterial load over years and decades.

An LDL of 70 mg/dL today does not erase prior years at 160 mg/dL. It does, however, stop new damage from accumulating at the prior rate, and sustained lower levels provide protection going forward.

Conversely, stopping treatment when numbers improve does not lock in the gains — it resumes atherogenic particle exposure at pre-treatment rates, often within weeks.

This is why clinical guidelines frame cholesterol treatment as long-term or lifelong for most patients: not because medications can never be reconsidered, but because the biological mechanism is cumulative, not corrective.

Benefit Scales With Baseline Risk

The absolute benefit of treatment is not uniform — it scales directly with baseline risk.

A patient with established coronary artery disease taking a statin reduces their absolute risk of a cardiovascular event by roughly 4–5 percentage points over five years. A low-risk primary prevention patient may see an absolute reduction of less than 1 percentage point over the same period, even with identical LDL lowering. (1)

This is why treatment intensity, targets, and the urgency of adherence are individualized — the higher the underlying risk, the larger the absolute gain from each percentage point of LDL reduction sustained over time. Secondary prevention patients, and those with diabetes or multiple risk factors, derive the most from consistent long-term therapy.

Adherence Is a Clinical Outcome

The adherence stakes are quantifiable.

Real-world data from cardiovascular patients shows that a 20% improvement in cardiovascular medication adherence is associated with 8% lower cardiovascular event rates and 12% lower mortality. (26) For statins specifically, the same analysis found a relative risk reduction of 0.90 for cardiovascular events per 20% adherence gain.

These are not trivial numbers. Adherence is not an administrative concern — it is a clinical outcome.

Why People Stop: The Evidence

Research on statin discontinuation consistently identifies the same drivers: beliefs about personal risk, concerns about harm, and gaps in communication — not primarily forgetting or logistics. (12)

Belief Drift

Belief drift is the most clinically important of these.

When treatment works, the patient feels well, numbers improve, and the original threat that prompted treatment fades from daily awareness. Absence of symptoms feels, at a psychological level, like evidence that treatment is no longer necessary.

The disease that requires treatment is the one the patient cannot feel — and this mismatch between subjective experience and biological reality is the engine of drift.

This is not a character flaw or a knowledge deficit. It is a predictable consequence of how human risk perception works: concrete daily costs (taking a pill, paying for medication, accepting uncertainty about side effects) are weighted more heavily than abstract future benefits that are statistically real but personally invisible.

Every chronic preventive therapy faces this challenge. Cholesterol treatment faces it acutely because the timeline is so long and the feedback so absent.

The Nocebo Cascade

The nocebo cascade adds a second layer.

A Danish nationwide cohort study found that negative statin-related media coverage was associated with increased early discontinuation — and that early discontinuation was associated with higher rates of myocardial infarction and cardiovascular death. (23)

Doubt, once reactivated by external narratives, compounds silently over months.

Practical Barriers

Practical barriers — insurance changes, pharmacy disruptions, cost, visit gaps — interact with belief drift. The combination is more likely to produce permanent discontinuation than either alone.

Managing Side Effects: What the Evidence Shows

Muscle Symptoms and the Nocebo Effect

Muscle complaints are among the most common reasons patients stop statins. (10,11) The clinical evidence on this is among the most important — and most misunderstood — in cholesterol medicine.

The SAMSON Trial (New England Journal of Medicine, 2020, with extended analysis in JACC, 2021) used a rigorous N-of-1 crossover design in patients who had previously stopped statins due to side effects. Participants cycled through statin, placebo, and no-tablet periods in randomized monthly sequences, rating symptoms daily. (16,17)

The findings:

Period	Average symptom intensity (0–100)
Statin months	16.3
Placebo months	15.4 (not significantly different from statin)
No-tablet months	8.0

Ninety percent of the symptom burden attributed to statins was also triggered by placebo. Six months after participants saw their own data, 50% had successfully restarted statins.

This phenomenon — symptoms arising from the act of taking a tablet rather than from the molecule itself — is the nocebo effect. The symptoms are real. The cause is expectation, not pharmacology, in the majority of cases.

The rechallenge data make the clinical implication concrete. A 2023 systematic review and meta-analysis (8 included trials; 7 contributing to the primary intolerance outcome) found that among patients believed to be statin-intolerant, 36% showed intolerance on blinded rechallenge with a statin compared with 26% on placebo (RR 1.40, 95% CI 1.23–1.60). (18)

The gap between those two figures — a 10 percentage-point absolute difference between statin and placebo rechallenge — suggests that the pharmacologic component of reported statin intolerance is substantially smaller than commonly perceived. The remainder reflects nocebo effect, coincidental symptoms, or other causes.

For many patients labeled as statin-intolerant, the intolerance is neither permanent nor primarily pharmacological — and structured evaluation often allows successful resumption.

The Structured Evaluation Approach

Because symptoms may reflect drug effects, expectations, drug interactions, thyroid or vitamin D abnormalities, increased exercise, viral illness, or unrelated conditions, the appropriate response to suspected statin side effects is structured evaluation — not immediate permanent discontinuation.

Approaches clinicians may consider:

• Structured rechallenge: Brief washout followed by restart at lower dose; most patients who tolerate even a reduced dose can be uptitrated gradually.
• Statin switch: Different statins have different properties; many patients who cannot tolerate one tolerate another well.
• Alternative dosing: Rosuvastatin 2–3 times weekly is tolerated by some patients who cannot manage daily dosing.

Non-statin alternatives with outcomes data — for genuine confirmed intolerance after structured rechallenge:

• Ezetimibe: ~18% LDL reduction as monotherapy, ~23% added to statin (IMPROVE-IT). (19)
• Bempedoic acid: ~21% LDL reduction in statin-intolerant patients; 13% reduction in cardiovascular events in CLEAR Outcomes (statin-intolerant population). (20)
• PCSK9 inhibitors: ~50–60% LDL reduction; 15% cardiovascular event reduction in FOURIER and ODYSSEY trials. (21,22)

A note on CoQ10: evidence for benefit in statin-associated muscle symptoms remains limited and inconsistent. It is generally considered safe but should not be taken as a substitute for structured evaluation.

Misattribution traps. Symptoms beginning after an increase in exercise intensity, a viral illness, dehydration, or a new medication are frequently attributed to statins when the actual cause is elsewhere.

Clinicians evaluating suspected statin-related symptoms typically examine: symmetry, timing relative to dose changes, resolution during washout, and recurrence on rechallenge. CK levels are reserved for specific clinical scenarios.

When symptoms require urgent evaluation, not troubleshooting. Chest pressure, shortness of breath, fainting, one-sided weakness, sudden speech difficulty, or severe muscle pain with dark urine or profound weakness are not side effects to work through. Call 911 or seek emergency care immediately.

Building Systems That Outlast Motivation

The clinical literature on long-term medication adherence across chronic diseases arrives at a consistent finding: patients who sustain treatment over years are not more disciplined than those who do not. They have better systems. (8,24)

This distinction matters.

Motivation is variable by nature — it responds to mood, stress, competing demands, and the passage of time. A treatment strategy that depends on motivation will inevitably encounter days, weeks, or months when motivation is insufficient.

The question is not how to sustain motivation but how to design a system that functions reliably in its absence.

Why Automaticity Is the Target

Research into habit formation and medication adherence shows that habit strength — the degree to which a behavior has become automatic in response to a stable cue — is positively correlated with adherence in the large majority of studies. (28)

As a behavior becomes more automatic, the likelihood of forgetting or choosing not to perform it decreases substantially. The mechanism is not willpower; it is the transfer of behavioral control from conscious deliberation to environmental cues.

A qualitative study of patients with hypertension in Los Angeles found that 50% described stable cue anchors as central to their medication routines — getting out of bed, morning coffee, dinner, bedtime. Crucially, the most effective anchors were those least likely to be disrupted by changes in daily schedule. (29)

The practical implication is specific: anchoring a medication to the most stable, least variable point in a daily routine is more reliable than anchoring it to a variable event.

The pathway is:

Stable cue → repeated behavior → automaticity → adherence without active deliberation

Designing that pathway deliberately — choosing the cue, placing the medication visibly at that cue point, repeating the pairing until it requires no active decision — is how long-term adherence is actually built.

Medication Synchronization: Evidence and Effect Size

Pharmacy synchronization programs — aligning all refill dates to a single monthly pickup — address one of the most common adherence failure modes: the logistics of refilling multiple medications on different cycles.

A study of approximately 23,000 Medicare patients with hypertension, hyperlipidemia, or diabetes found that synchronization programs improved proportion of days covered by 3 percentage points (0.84 to 0.87). The effect was three times larger in patients with low baseline adherence — precisely the patients whose systems most needed structural support. (25)

A separate analysis of statin-specific adherence following appointment-based medication synchronization found improvement from 80.06% to 82.31% at 12 months (p<0.01). (27)

The absolute numbers are modest. The mechanism is instructive: synchronization removes the refill decision.

Rather than requiring a patient to notice, remember, and act on four different refill timelines each month, one pickup handles all medications. The cognitive burden shrinks. Missed refills — and the gaps in coverage they produce — decrease.

The fewer active decisions required to stay on treatment, the more reliably the system works.

Designing Around Predictable Failure Points

In long-term statin therapy, adherence breaks most reliably at transitions: insurance or pharmacy changes, travel, acute illness, shifts in routine, periods of “good numbers.” These are not personal failures — they are predictable system vulnerabilities that recur in research across patient populations.

Recognizing them as system events, not personal ones, enables preemptive design:

Transition point	System response
Insurance or pharmacy change	Verify next refill before the change takes effect
Travel	Carry-on supply plus written medication list
Acute illness	Pre-agreed protocol with clinician for when to pause and when to restart
“Good numbers”	Explicit clinician conversation establishing that numbers improving = treatment working, not treatment unnecessary
Routine disruption (move, job change)	Re-anchor medication to new stable cue immediately

The goal is not vigilance — it is anticipation. A patient who has already decided what to do at the next insurance change does not have to make that decision under pressure.

Making It Automatic: A Practical Checklist

Strategies with consistent support across adherence research:

• Cue anchoring: Pair medication with the most stable, least variable cue in your daily routine — not “when I remember” but a specific, recurrent event. Morning coffee, toothbrushing, and bedtime consistently appear as the most reliable anchors in patient-reported data.
• Visibility: Medication kept on the counter, in a weekly organizer, or at the cue location is taken more reliably than medication stored out of sight. (7) Environmental design shapes behavior before the conscious decision occurs.
• Pharmacy synchronization and auto-refill: Aligning all refill dates eliminates the multi-timeline tracking problem. Ninety-day supplies via mail order further reduce the refill frequency. Reminder apps and automated alerts can assist but work best when paired with underlying system design rather than substituting for it. (9)
• Travel preparation: A designated travel supply — a week’s worth in carry-on luggage plus a written medication list — addresses one of the most common interruption points.
• One support person: Behavioral research across chronic disease consistently identifies social support as a moderator of adherence. A single person who knows what you are managing and can ask — without judgment — how it is going provides accountability that reduces drift.
• If-then planning: Specifying in advance exactly when, where, and how you will take a medication substantially increases follow-through compared to general intention alone — a finding consistent across hundreds of health behavior trials.

The format is simple: “If [specific cue], I will [specific action].” Examples: “If I pour my morning coffee, I will take my statin before the first sip.” “If I pack for travel, I will add my medications to the carry-on before anything else.”

The power is in the specificity — the decision is made once, in advance, rather than each morning under competing demands.

The Psychology of Long-Term Treatment

The Stop–Start Pattern

Interruptions are common and do not constitute failure. What distinguishes patients who restart from those who stop permanently is whether the concerns that drove the interruption were ever addressed.

Patients who restart tend to treat adherence as “good enough most of the time” rather than all-or-nothing, bring problems to clinicians rather than quietly stopping, and maintain follow-up when things feel off.

Patients who stop permanently typically had concerns — about side effects, about benefit, about whether treatment ever made sense — that were never directly addressed.

The practical question after any interruption is not whether you failed. It is whether the concern that caused the interruption has been resolved. If it has, restarting is clinically straightforward. If it has not, the same pattern will recur.

What to Do After a Gap

If doses are missed or treatment was stopped:

• Clinicians generally advise against doubling up without clinician guidance
• The priority is identifying the reason: side effects, logistics, doubt about benefit, or something else
• When reconnecting with a clinician, useful information includes a current medication list, a timeline of any symptoms or concerns, what changed in the period before stopping, and what you have already tried
• If the gap was caused by a refill or insurance problem, fixing the system first makes restarting more likely to persist

Most clinicians approach interrupted therapy as information to act on, not a failure to judge.

Lifestyle Factors

Medication and lifestyle do not do the same thing.

Statins and other lipid-lowering therapies address atherogenic particle burden directly. Lifestyle changes — dietary pattern, physical activity, weight, alcohol reduction — address blood pressure, insulin sensitivity, inflammation, and cardiometabolic risk in ways that medication does not fully reach.

For most patients, the combination delivers more than either approach alone.

That said, individual dietary response varies substantially. Some patients, particularly those in lower-risk primary prevention with favorable genetics and significant saturated fat intake, experience LDL reductions from dietary change that meaningfully reduce their medication needs. This is worth exploring with a clinician before assuming medication is the only lever.

Dietary Evidence

The Mediterranean pattern — olive oil, nuts, fish, vegetables, whole grains, legumes; less red meat and processed food — has the strongest evidence for reducing cardiovascular events in the context of cholesterol management. (13)

For those specifically targeting LDL reduction through diet, the Portfolio Diet combines four food components with established cholesterol-lowering mechanisms: (14)

Component	Daily Amount	Food Sources
Plant sterols	2 g	Fortified foods, spreads
Viscous fiber	10 g	Oatmeal, psyllium, beans
Soy protein	25 g	Soy milk, tofu, edamame
Tree nuts	45 g	Almonds, walnuts, cashews

Dramatic dietary overhauls rarely persist. Gradual substitutions that become habitual tend to produce more durable benefit than intense short-term changes. A registered dietitian can individualize the approach.

Physical Activity

The threshold for cardiovascular benefit is lower than most people assume: (15)

• 150 minutes of moderate activity per week (brisk walking qualifies), or
• 75 minutes of vigorous activity per week
• Any increase from a sedentary baseline provides some benefit

Type matters less than consistency. For patients with established cardiovascular conditions, activity recommendations are individualized by clinicians.

Long-Term Perspectives

What to Expect Over Time

First 6–12 months: Establishing routines, addressing side effects if they arise, seeing how labs respond, making lifestyle adjustments that are actually sustainable.

Beyond two years: Navigating life transitions (insurance changes, moves, health changes), maintaining treatment through disruptions, periodic reassessment with the clinical team.

What Ongoing Management Actually Means

Patients sometimes disengage because “long-term management” feels undefined and burdensome. In practice it is not:

• Labs: Annually for stable patients; more frequently during medication adjustments or significant health changes.
• Medication review: After major life events — new diagnoses, significant weight change, pregnancy planning, aging — treatment may be revisited.
• Coordination: Cholesterol management typically intersects with blood pressure, glucose, and other cardiovascular risk factors; the clinical visit is the integration point.

The goal is not constant vigilance. It is periodic confirmation that the approach still fits.

Medications: Reference Tables

Statins

Brand Name	Generic Name	Generic Available
Lipitor	atorvastatin	Yes
Crestor	rosuvastatin	Yes
Zocor	simvastatin	Yes
Pravachol	pravastatin	Yes
Lescol	fluvastatin	Yes
Livalo	pitavastatin	Yes

Combination Pills

Brand Name	Generic Components	What’s Combined
Vytorin	simvastatin/ezetimibe	Statin + absorption blocker
Liptruzet	atorvastatin/ezetimibe	Statin + absorption blocker
Roszet	rosuvastatin/ezetimibe	Statin + absorption blocker
Caduet	atorvastatin/amlodipine	Statin + blood pressure medication
Nexlizet	bempedoic acid/ezetimibe	Non-statin + absorption blocker

Other Cholesterol Medications

Brand Name	Generic Name	Typical Use
Zetia	ezetimibe	Often added to statins
Welchol	colesevelam	Bile acid sequestrant
Questran	cholestyramine	Bile acid sequestrant
Trilipix/Tricor	fenofibrate	Elevated triglycerides
Lopid	gemfibrozil	Elevated triglycerides
Nexletol	bempedoic acid	Non-statin option
Vascepa	icosapent ethyl	Prescription omega-3
Lovaza	omega-3-acid ethyl esters	Prescription omega-3

Injectable PCSK9 Inhibitors

Brand Name	Generic Name	Frequency	Outcomes Evidence
Repatha	evolocumab	Every 2 weeks or monthly	Cardiovascular event reduction established (FOURIER) (21)
Praluent	alirocumab	Every 2 weeks	Cardiovascular event reduction established (ODYSSEY) (22)
Leqvio	inclisiran	Twice yearly after initial doses	LDL reduction established; cardiovascular outcomes trial (ORION-4) ongoing — event reduction not yet confirmed

Generic vs. Brand

Generic medications are required to deliver essentially the same amount of active drug to the bloodstream as brand versions, and research shows similar LDL reductions and cardiovascular outcomes between generic and brand statins. (2,3,4,5,6)

Pharmacy switches that change a pill’s appearance can occasionally trigger doubt and heighten symptom awareness — a nocebo effect distinct from any pharmacological difference. If this occurs, it is worth discussing with a clinician or pharmacist rather than stopping.

Cost Management

Strategy	How to Access
Generic substitution	Discuss with prescriber
Prescription discount programs	Free apps and pharmacy comparison websites
Mail-order pharmacy (90-day supply)	Through insurance plan
Warehouse pharmacies	Variable membership requirements
Manufacturer patient assistance	Company websites; prescriber office can assist

Prior Authorization: Documentation Typically Required

• Recent lipid panels (often within past 12 months)
• Record of previous medication trials
• Cardiovascular risk assessment
• Documentation of side effects or intolerances

If denied: request the denial letter, identify which criteria are unmet, resubmit with clearer documentation, and ask about peer-to-peer review.

Travel Checklist

• Adequate supply including buffer for delays
• Written medication list with doses and prescriber contacts
• All medications in carry-on luggage
• Confirmed pharmacy access at destination if needed

Topics for Healthcare Visits

• Whether current treatment is achieving goals
• Whether any symptoms might be medication-related
• Insurance changes and available alternatives
• Cost concerns
• How management may evolve with aging or changing health

Key Points

Adherence is a clinical outcome, not an administrative one. A 20% improvement in cardiovascular medication adherence translates to measurably lower event rates and lower mortality in real-world data. The biology of what sustained treatment does differs from the biology of intermittent treatment. (26)

Most apparent statin intolerance is reversible on structured evaluation. The SAMSON trial showed 90% of attributed symptom burden also occurred on placebo. The 2023 rechallenge meta-analysis showed a 10 percentage-point absolute difference in intolerance between statin and placebo on blinded rechallenge — meaning the pharmacological component is smaller than commonly perceived. Structured evaluation before permanent discontinuation is the clinically appropriate response.

Belief drift is the primary mechanism of long-term discontinuation. Effective treatment removes symptoms and improves numbers — and in doing so, removes the perceived urgency of taking it. This is predictable and manageable, but it requires explicit acknowledgment rather than assuming patients will intuitively understand that working treatment should be continued.

Systems outperform motivation for long-term adherence. Research on habit formation and medication adherence shows that automaticity — not discipline — is what sustains behavior over years. The target is a stable cue, consistently paired with the behavior, until it requires no active decision.

Known transitions are the most common points of permanent discontinuation — and the most amenable to advance planning. Insurance changes, travel, illness, and “good labs” are predictable system failure points. Designing around them before they occur is more effective than recovering from them after.

The Bottom Line

Cholesterol management succeeds or fails over decades, not appointments.

The clinical trial evidence establishes what sustained LDL reduction can achieve: meaningful reductions in heart attacks, strokes, and cardiovascular death, scaling with the size and duration of LDL lowering. (1) That benefit reaches patients only if treatment is actually taken, consistently, over years.

The single largest gap between what the evidence shows and what patients experience is not drug efficacy or side effects. It is discontinuation — driven by belief drift, unaddressed concerns, and systems that require daily conscious decisions rather than automatic behavior.

Long-term cholesterol management, well designed, requires very little from any given day: pills taken at a consistent time, refills handled automatically, periodic labs confirming the approach is working, and honest conversations when concerns arise. No constant vigilance. No daily urgency. A system designed to run in the background, requiring almost nothing from motivation.

The direction of treatment matters more than the smoothness of any single day.

Series Conclusion

This series has covered cholesterol testing, treatment targets, medications, lifestyle approaches, special populations, and long-term management.

The central theme throughout: cardiovascular protection is not about achieving a favorable number at a single point in time. It is about decades of sustained exposure management — a quieter and more enduring project than any dramatic intervention.

The specific decisions — which medication, which target, which trade-offs — belong to you and your clinical team. What this series tried to provide is the understanding that makes those conversations more equal.

Key Terms

Adherence: The degree to which a patient takes medication as prescribed, typically measured as proportion of days covered (PDC). A clinical outcome in its own right, not just a behavioral concern; small percentage-point improvements translate to measurable event reduction.

Automaticity: The state in which a behavior is triggered reliably by an environmental cue without requiring active decision. The target outcome of habit formation; the mechanism by which long-term adherence becomes sustainable across variations in motivation.

Belief drift: The gradual shift in a patient’s perception that effective preventive treatment is no longer necessary, driven by the absence of felt symptoms during successful therapy. The primary mechanism of long-term statin discontinuation.

Cue anchoring: The deliberate pairing of a medication-taking behavior with a stable, recurring daily event (morning coffee, toothbrushing, bedtime) to create automaticity over time.

Cumulative exposure: The total atherogenic particle burden circulating through the arteries over years and decades. The biological driver of atherosclerotic disease — not any single LDL measurement.

If-then planning: A behavioral strategy in which the specific cue, action, location, and timing of a behavior are decided in advance. Consistently associated with higher follow-through than general intention.

Medication synchronization: A pharmacy program that aligns all of a patient’s refill dates to a single monthly pickup. Reduces the cognitive burden of multi-medication tracking and modestly improves adherence, with larger effect in patients with low baseline adherence.

Nocebo effect: The phenomenon by which expectation of harm produces real symptoms that are not caused by the pharmacology of the drug. Accounts for the majority of muscle symptoms attributed to statins in blinded trials.

Proportion of days covered (PDC): The standard measure of medication adherence, expressed as the fraction of days in a given period for which the medication was available. PDC ≥80% is the conventional threshold for “adherent.”

SAMSON trial: An N-of-1 crossover trial in patients who had stopped statins due to side effects, demonstrating that 90% of the symptom burden attributed to statins also occurred on placebo. A foundational study of the nocebo effect in cholesterol therapy.

Structured rechallenge: A clinician-guided process for re-evaluating apparent statin intolerance, typically involving brief washout, restart at lower dose, and graduated uptitration. Most patients who underwent structured rechallenge in randomized trials successfully resumed statin therapy.

References

1. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
2. U.S. Food and Drug Administration. Generic Drug Facts. FDA.gov/drugs/generic-drugs/generic-drug-facts.
3. Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43(10):1583–1597.
4. Jackevicius CA, Tu JV, Ross JS, et al. Use of generic atorvastatin and health outcomes after generic entry. Circ Cardiovasc Qual Outcomes. 2014;7(3):383–390.
5. Gagne JJ, Choudhry NK, Kesselheim AS, et al. Comparative effectiveness of generic and brand-name statins on patient outcomes. Ann Intern Med. 2014;161(6):400–407.
6. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease. JAMA. 2008;300(21):2514–2526.
7. Zedler BK, Kakad P, Colilla S, et al. Does packaging with a calendar feature improve adherence to self-administered medication for long-term use? A systematic review. Clin Ther. 2011;33(1):62–73.
8. Conn VS, Ruppar TM, Enriquez M, Cooper P. Medication adherence interventions that target subjects with adherence problems: systematic review and meta-analysis. Res Social Adm Pharm. 2016;12(2):218–246.
9. Vervloet M, Linn AJ, van Weert JC, et al. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication. J Am Med Inform Assoc. 2012;19(5):696–704.
10. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement. Eur Heart J. 2015;36(17):1012–1022.
11. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–e81.
12. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings. Ann Intern Med.2013;158(7):526–534.
13. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34.
14. Jenkins DJ, Jones PJ, Lamarche B, et al. Effect of a dietary portfolio of cholesterol-lowering foods on serum lipids in hyperlipidemia. JAMA. 2011;306(8):831–839.
15. Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. JAMA.2018;320(19):2020–2028.
16. Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383(22):2182–2184.
17. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210–1222.
18. Kraut R, Wierenga F, Molstad E, et al. Intolerance upon statin rechallenge: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2023;18(12):e0295857.
19. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
20. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–1364.
21. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
22. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107.
23. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J.2016;37(11):908–916.
24. Kini V, Ho PM. Interventions to improve medication adherence: a review. JAMA. 2018;320(23):2461–2473.
25. Krumme AA, Glynn RJ, Schneeweiss S, Gagne JJ, Dougherty JS, Brill G, Choudhry NK. Medication synchronization programs improve adherence to cardiovascular medications and health care use. Health Aff (Millwood). 2018;37(1):125–133.
26. Chen C, Li X, Su Y, You Z, Wan R, Hong K. Adherence with cardiovascular medications and the outcomes in patients with coronary arterial disease: “Real-world” evidence. Clin Cardiol. 2022;45(12):1220–1228.
27. Dao N, Lee S, Hata M, Sarino L. Impact of appointment-based medication synchronization on proportion of days covered for chronic medications. Pharmacy (Basel). 2018;6(2):44.
28. Becker S, Brandl C, Meister S, et al. Habit strength, medication adherence, and habit-based mobile health interventions across chronic medical conditions: systematic review. JMIR Mhealth Uhealth. 2020;8(4):e13924.
29. Ghai I, Palimaru A, Ebinger JE, Barajas D, Vallejo R, Morales M, Linnemayr S. Barriers and facilitators of habit building for long-term adherence to antihypertensive therapy among people with hypertensive disorders in Los Angeles, California: a qualitative study. BMJ Open. 2024;14(7):e079401.